

Table S1 Mean difference (95% CIs) of CRP and PCT

PCT (Right upper part)					
CRP	XYP plus WM	1.76 (-2.05, 5.58)	2.42 (-1.15, 5.99)	0.03 (-3.70, 3.75)	-0.65 (-2.89, 1.58)
(Left lower part)	3.80 (-2.20, 9.79)	XBJ plus WM	0.66 (-0.69, 2.01)	-1.74 (-3.46, -0.01)	1.99 (-1.83, 5.80)
	-1.05 (-5.30, 3.20)	-4.84 (-9.07, -0.62)	WM	-2.40 (-3.48, -1.32)	-1.31 (-3.09, 0.47)
	0.44 (-3.75, 4.62)	-3.36 (-7.65, 0.93)	1.48 (0.74, 2.23)	TRQ plus WM	1.09 (-1.00, 3.17)
	3.21 (-1.12, 7.54)	1.24 (-0.17, 2.64)	-0.25 (-1.84, 1.34)	-0.27 (-4.54, 3.99)	RDN plus WM

The numbers in bold in the table indicate that there are statistically significant differences between this group and the RT group. CIs, confidence intervals; CRP, C-reactive protein; PCT, procalcitonin; WM, Western Medicine; XBJ, Xuebijing injection; RDN, injection; TRQ, Tanreqing injection; XYP, Xiyanping injection.

Table S2 Mean difference (95% CIs) of WBC and NE%

NE% (Right upper part)					
WBC	XYP plus WM	-1.38 (-5.37, 2.61)	4.21 (0.85, 7.57)	1.05 (-2.93, 5.02)	-5.31 (-10.54, -0.08)
(Left lower part)	-0.42 (-2.17, 1.34)	XBJ plus WM	5.59 (3.45, 7.73)	2.43 (-0.60, 5.46)	-3.93 (-8.48, 0.62)
	-1.92 (-3.64, -0.20)	-1.50 (-1.89, -1.12)	WM	-3.16 (-5.30, -1.03)	-9.52 (-13.53, -5.51)
	-1.04 (-2.80, 0.73)	-0.62 (-1.18, -0.07)	0.88 (0.47, 1.29)	TRQ plus WM	-6.36 (-10.90, -1.82)
	0.45 (-0.45, 1.35)	-0.21 (-2.05, 1.64)	1.95 (1.14, 2.76)	1.07 (0.17, 1.98)	RDN plus WM

The numbers in bold in the table indicate that there are statistically significant differences between this group and the WM group. CIs, confidence intervals; WBC, white blood cells; NE, neutrophils; WM, Western Medicine; XBJ, Xuebijing injection; RDN, injection; TRQ, Tanreqing injection; XYP, Xiyanping injection.

Table S3 Mean difference (95% CIs) of IL-6 and IL-8

IL-8 (Right upper part)					
IL-6	XYP plus WM	4.49 (-4.72, 13.70)	1.16 (-2.83, 5.14)	-1.85 (-6.41, 2.70)	0.30 (-7.96, 8.56)
(Left lower part)	3.92 (0.63, 7.20)	XBJ plus WM	-2.88 (-14.36, 8.60)	2.80 (-5.46, 11.05)	-0.21 (-8.16, 7.74)
	-1.71 (-4.05, 0.64)	-5.62 (-7.93, -3.32)	WM	5.67 (-2.31, 13.65)	-2.66 (-5.62, 10.95)
	0.25 (-1.95, 2.46)	-3.66 (-6.10, -1.22)	1.96 (1.16, 2.76)	TRQ plus WM	-3.01 (-5.23, -0.79)
	4.51 (2.00, 7.02)	0.86 (-0.42, 2.15)	-1.10 (-2.61, 0.41)	-0.69 (-3.06, 1.68)	RDN plus WM

The numbers in bold in the table indicate that there are statistically significant differences between this group and the WM group. CIs, confidence intervals; IL-6, interleukin-6; IL-8, interleukin-8; WM, Western Medicine; XBJ, Xuebijing injection; RDN, injection; TRQ, Tanreqing injection; XYP, Xiyanping injection.

Table S4 Mean difference (95% CIs) of TNF- α

TNF- α

XYP plus WM		XBJ plus WM		WM		TRQ plus WM		RDN plus WM	
-1.50 (-3.51, 0.52)		-5.59 (-7.65, -3.52)							
0.20 (-1.75, 2.15)		-3.89 (-6.02, -1.77)		1.69 (1.21, 2.18)					
4.21 (2.05, 6.37)		1.01 (0.19, 1.83)		-0.68 (-1.64, 0.27)			-1.47 (-3.52, 0.59)		

The numbers in bold in the table indicate that there are statistically significant differences between this group and the WM group. CIs, confidence intervals; TNF- α , tumor necrosis factor- α ; XYP, Xiyanping injection; WM, Western Medicine; XBJ, Xuebijing injection; RDN, injection; TRQ, Tanreqing injection.

Appendix 1: Search strategy of EMBASE.








- #1 'pulmonary disease, chronic obstructive': ab, ti
- #2 'bronchitis, chronic': ab, ti OR emphysema: ab, ti
- #3 copd: ab, ti
- #4 'chronic obstructive pulmonary': ab, ti
- #5 coad: ab, ti
- #6 'chronic obstructive airway': ab, ti
- #7 'chronic obstructive lung': ab, ti
- #8 'chronic obstructive bronchopulmonary': ab, ti
- #9 'chronic obstructive respiratory': ab, ti
- #10 'chronic airflow obstruction': ab, ti
- #11 'chronic airflow obstructive': ab, ti
- #12 'chronic bronchitis': ab, ti
- #13 'pulmonary emphysema': ab, ti
- #14 'lung emphysema': ab, ti
- #15 'chronic airflow limitation': ab, ti
- #16 'reduning injection': ab, ti
- #17 'tanreqing injection': ab, ti
- #18 'xuebijing injection': ab, ti
- #19 'xiyanping injection': ab, ti
- #20 'randomized controlled trial': ab, ti
- #21 'controlled clinical trial': ab, ti
- #22 randomized: ab, ti
- #23 randomly: ab, ti
- #24 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15
- #25 #16 OR #17 OR #18 OR #19
- #26 #20 OR #21 OR #22 OR #23
- #27 #24 AND #25 AND #26

Appendix 2: Node-splitting for Outcomes

	P value (CRP)	P value (PCT)	P value (WBC)	P value (IL-6)	P value (IL-8)	P value (TNF- α)
A C	0.991	0.995	0.986	0.997	0.996	0.999
B C	0.458	0.999	0.993	0.156	0.263	0.155
B D	0.173	/	/	0.143	0.341	0.116
B E	0.878	/	/	0.807	0.996	0.953
C D	0.547	0.746	0.618	0.558	0.603	0.850
C E	0.891	0.386	0.907	0.202	/	0.056
D E	0.813	0.673	0.732	0.070	/	0.064


Note: A: Reduning injection plus WM; B: Tanreqing injection plus WM; C: WM; D: Xuebijing injection plus WM; E: Xiyanping injection plus WM. WM: Western Medicine.

Appendix 3: The figure of the cumulative probabilities for outcomes



Note: A, CRP; B, PCT; C, WBC; D, NE%; E, IL-6; F, IL-8. G, TNF- α . RDN, Reduning injection; WM, Western Medicine; XYP, Xiyanning injection; TRQ, Tanreqing injection; XBJ, Xuebijing injection; CRP, C-reactive protein; PCT, procalcitonin; WBC, white blood cells; NE, neutrophils; IL-6, interleukin-6; IL-8, interleukin-8; TNF- α , tumor necrosis factor- α .

Appendix 4: Funnel plots of outcomes.



Note: A, WBC; B, NE%; C, IL-6; D, IL-8. E, TNF- α . A, Reduning injection plus Western Medicine; B, Tanreqing injection plus Western Medicine; C, Western Medicine; D, Xuebijing injection plus Western Medicine; E, Xiyanning injection plus Western Medicine; WBC, white blood cells; NE, neutrophils; IL-6, interleukin-6; IL-8, interleukin-8; TNF- α , tumor necrosis factor- α .